Longitudinal Epidemiology of Mucormycosis Within the Veterans Health Administration: A Retrospective Cohort Study Over a 20‐Year Period
Mycoses · 2024
DOI: 10.1111/myc.13794 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Mycoses, 2024. Verfasst von Nirmal Muthukumarasamy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: Mucormycosis, Antifungal Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Mucormycosis is a rare but critical infection. Due to its rarity, there is scarce evidence about the longitudinal changes in the epidemiology of mucormycosis in the US.
Objectives
We investigated the longitudinal epidemiology, detailed clinical characteristics, treatment and outcomes of patients with mucormycosis within the US Veterans Health Administration (VHA) over 20‐year period. Patients/Methods All adult patients who were admitted to an acute‐care hospital with a diagnosis of mucormycosis within the VHA from January 2003 to December 2022.
Results
Our study included 201 patients from 68 hospitals. Incidence rates of mucormycosis increased from 1.9 per 100,000 hospitalisations in 2003 to 3.3 per 100,000 hospitalisations in 2022, with a peak incidence at 5.9 per 100,000 hospitalisations in 2021, when the Delta wave of COVID‐19 hit the US. Rhino‐orbital (37.3%) and pulmonary mucormycosis (36.8%) were the most common types of infection. Diabetes mellitus (59.1%) and leukaemia (28.9%) were most common comorbidities predisposing to mucormycosis. Use of posaconazole or isavuconazole increased over time. The 90‐day and 1‐year mortalities were 35.3% and 49.8%, respectively. The mortality was lower in more recent years (2013–2017, 2018–2022) compared to earlier years (2003–2007). Age ≥65 (adjusted odds ratio [aOR]: 3.47, 95% CI 1.59–7.40), leukaemia as a comorbidity (aOR: 2.66, 95% CI 1.22–5.89) and central nervous system infection (aOR: 10.59, 95% CI 2.81–44.57) were significantly associated with higher 90‐day mortality.
Conclusions
Our longitudinal cohort study suggests the increasing incidence rates but lower mortality of mucormycosis over this 20‐year period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.
- Center for Access & Delivery Research & Evaluation (CADRE), Iowa City Veterans Affairs Health Care System, Iowa City, Iowa, USA.
ORCID-Profile: Nirmal Muthukumarasamy, Hiroyuki Suzuki
Zitieren
APA
Muthukumarasamy, N., & Suzuki, H. (2024). Longitudinal Epidemiology of Mucormycosis Within the Veterans Health Administration: A Retrospective Cohort Study Over a 20‐Year Period. Mycoses. https://doi.org/10.1111/myc.13794
Vancouver
Muthukumarasamy N, Suzuki H. Longitudinal Epidemiology of Mucormycosis Within the Veterans Health Administration: A Retrospective Cohort Study Over a 20‐Year Period. Mycoses. 2024. doi:10.1111/myc.13794
BibTeX
@article{Muthukumarasamy2024,
author = {Muthukumarasamy, Nirmal and Suzuki, Hiroyuki},
title = {Longitudinal Epidemiology of Mucormycosis Within the Veterans Health Administration: A Retrospective Cohort Study Over a 20‐Year Period},
journal = {Mycoses},
year = {2024},
doi = {10.1111/myc.13794}
}
EUVIMED